Financing channel feed – Endpoints News

Financing channel feed

A unicorn joins this week’s stampede of biotechs into the red-hot Nasdaq casino

7 years ago

Vant commander Ramaswamy heads back to Nasdaq with a $150M pitch — are investors ready to forgive Axovant?

7 years ago

Biogen vet George Scangos jumps on the board at upstart MS case manager Octave, backed by Section 32

7 years ago

Thiel-backed Compass adds $49M to A round, bringing total to $132M

7 years ago

12 top China VCs you need to know who are making a transpacific splash (Part 2)

7 years ago

Forbion raises $316M to tap the potential of European biotech plays

7 years ago

As biotech funds sprout around the globe, Sanofi and government bank are setting up a $292M operation in France

7 years ago

7 things you need to know now about raising biotech cash in China (Part 1)

7 years ago

A roaring Rubius sets out to snag $1.8B market cap in $200M IPO

7 years ago

Abingworth lines up $315M to bet on a new generation of transatlantic biotechs

7 years ago

With tech from Spinraza's maker, French startup Dynacure gets $55M to tackle neuromuscular disease

7 years ago

Another IPO frenzy? Two US biotechs head to Hong Kong for a public market debut

7 years ago

Hong Kong exchange picks up steam with two biotech IPOs from Innovent, MicuRx

7 years ago

RIP XTuit: Great brains, hot target and vet CEO Deborah Dunsire in charge couldn’t stop this biotech from going down

7 years ago

With $100M in fresh backing and a new TCR initiative, Athenex launches China JV

7 years ago

GSK-backed Liquidia takes a seat at the IPO table, looking for a $57.5M stake to take on United Therapeutics

7 years ago

Forget the biotech mega-round. Try the $200M-plus China 'ultra' on for size

7 years ago

How does the first half of 2018 measure up against the last 7 years for biotech IPOs?

7 years ago

C-Bridge hands Nuance Biotech $35M, opening doors to more China licensing deals

7 years ago

It’s a record! Biotech IPO frenzy outpaces 2017 in half the time as 4 new arrivals on Nasdaq raise $556M

7 years ago

IPO bound? Crossovers join big syndicate backing Precision BioSciences’ $110M gene editing round

7 years ago

Neon joins the biotech IPO fiesta on Nasdaq, bagging $100M in the latest display of enthusiasm for drug developers

7 years ago

CAR macrophage tumor tech created by UPenn star scientists gets $53M

7 years ago

Bill Haney believes there’s a better way to build a biotech — and now he has $100M more at Skyhawk to prove it

7 years ago

First page Previous page 125 126 127128129 130 131 Next page Last page